Evaluation of IL-6 and IL-8 as prognostic markers after local ablation therapy of breast or abdominal lesions (ESTIMATE)

Evaluation of IL-6 and IL-8 as prognostic markers after local ablation therapy of breast or abdominal lesions (ESTIMATE) - ESTIMATE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00010587

Enrollment

800

Registered

2019-05-23

Start date

2017-07-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Indication for local ablative therapy of malignancies C50 C22 C20

Interventions

Group 1: Parameters such as IL-6 and IL-8 following locally ablative therapy as the radioembolization prognostic value for overall survival have not been studied. Evaluating the valence of IL-6 and IL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • primary or secondary metastsis of lungs-cancer and HCC. • male or female, > 18 years • Indication of HDR brachytherapy, microwave ablation or radiofrequency ablation in one or more sessions • Patient confirms all study procedures (taking blood sample like routine diagnostics) • Signed informed consent

Exclusion criteria

Exclusion criteria: • contraindication for local ablative therapies Life expectancy <3 months

Design outcomes

Primary

Measure	Time frame
Evaluation of pre-treatment IL-6 and IL-8 concentration as prognostic marker for overall survival after image-guided therapy lokalablativer (HDR, MWA, RFA) intrathoracic or intra-abdominal malignancies.	—

Countries

Germany

Contacts

Public ContactChristel Besseler

Klinik und Poliklinik für Radiologie Klinikum der Universität München Campus Großhadern

christel.besseler@med.uni-muenchen.de(089) 4400-73647

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 8, 2026